Yet another leak is plaguing Teva Pharmaceuticals. This time, the drugmaker is chafing over a report in an Israeli business publication called The Marker that published an internal, five-year forecast showing that profits from its all-important Copaxone multiple sclerosis drug will drop 42 percent in 2014.
Hey, check out all the research scientist jobs. Post your resume today!
